Action of 1,25-dihydroxyvitamin D3 and a diphosphonate on calcium metabolism in rats.
The effect of 1,25-dihydroxycholecalciferol (1,25-(OH)2D3) on Ca balance, 45Ca kinetics, and bone morphology has been studied in control rats and rats given disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP), 10 mg P/kg sc per day. This large dose of EHDP is known to inhibit bone mineralization and intestinal calcium absorption and to depress the endogenous production of 1,25-(OH)2D3. In conctrol rats, 1,25-(OH)2D3 increased intestinal calcium absorption. However, in contrast to the enhanced calcium absorption that results from an augmentation of dietary calcium, the 1,25(OH)2D3-induced augmentation of calcium absorption does not lead to a rise in calcium retention, the intestinal effect being matched by an increased excretion of urinary calcium. The EHDP-induced decrease of intestinal calcium absorption could be completely prevented by the concomitant administration of 1,25-(OH)2D3 but not the inhibition of bone mineralization. Therefore, in contrast to the impairment of calcium absorption, that of bone mineralization brought about by large doses of EHDP cannot be merely attributed to a decreased production of 1,25-(OH)2D3.
D000818:Animals; D001862:Bone Resorption; D002118:Calcium / Q000097:blood / Q000378:metabolism* / Q000652:urine; D004100:Dihydroxycholecalciferols / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004838:Epiphyses / Q000033:anatomy & histology / Q000187:drug effects; D012968:Etidronic Acid / Q000494:pharmacology*; D005260:Female; D006887:Hydroxycholecalciferols / Q000494:pharmacology*; D007408:Intestinal Absorption / Q000187:drug effects; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D010012:Osteogenesis / Q000187:drug effects; D051381:Rats
D004100:Dihydroxycholecalciferols; D006887:Hydroxycholecalciferols; D009943:Organophosphorus Compounds; D012968:Etidronic Acid; D002118:Calcium